Novel prediction of anticancer drug chemosensitivity in cancer cell lines: Evidence of moderation by microRNA expressions

Abstract

The objectives of this study are (1) to develop a novel "moderation" model of drug chemosensitivity and (2) to investigate if miRNA expression moderates the relationship between gene expression and drug chemosensitivity, specifically for HSP90 inhibitors applied to human cancer cell lines. A moderation model integrating the interaction between miRNA and gene expressions was developed to examine if miRNA expression affects the strength of the relationship between gene expression and chemosensitivity. Comprehensive datasets on miRNA expressions, gene expressions, and drug chemosensitivities were obtained from National Cancer Institute's NCI-60 cell lines including nine different cancer types. A workflow including steps of selecting genes, miRNAs, and compounds, correlating gene expression with chemosensitivity, and performing multivariate analysis was utilized to test the proposed model. The proposed moderation model identified 12 significantly-moderating miRNAs: miR-15b*, miR-16-2*, miR-9, miR-126*, miR-129*, miR-138, miR-519e*, miR-624*, miR-26b, miR-30e*, miR-32, and miR-196a, as well as two genes ERCC2 and SF3B1 which affect chemosensitivities of Tanespimycin and Alvespimycin - both HSP90 inhibitors. A bootstrap resampling of 2,500 times validates the significance of all 12 identified miRNAs. The results confirm that certain miRNA and gene expressions interact to produce an effect on drug response. The lack of correlation between miRNA and gene expression themselves suggests that miRNA transmits its effect through translation inhibition/control rather than mRNA degradation. The results suggest that miRNAs could serve not only as prognostic biomarkers for cancer treatment outcome but also as interventional agents to modulate desired chemosensitivity.

RETRACTED ARTICLE: MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel

“…Similarly, previous literature has shown that miR-624 is upregulated in ESCC to an extent that is positively correlated with the progression of ESCC [ 10 ]. In addition, miR-624 has been confirmed to function as a potential candidate to regulate the sensitivity to chemotherapy in cancer treatment [ 26 ]. Findings from the current study demonstrated that miR-624 was expressed at a higher level in the drug-resistant ESCC cell line KYSE410 than in the drug-sensitive cell line KYSE150.…”

miR-138–Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics

“…Recent studies have demonstrated a key role of miR-138 in the progression and metastasis (39) and the development of chemoresistance in cancers of different origins (29;40). We found miR-138 to specifically target K2 and to suppress its expression.…”

Pan-Cancer analysis of somatic mutations in miRNA genes

“…Hsa-miR-519e belongs to the large (>50) miR-515 family coded in a cluster on 19q13.42. It is not a highly validated miRNA gene and is not well recognized as a cancer-related miRNA; however, it was shown to have decreased levels in epithelial ovarian cancer, increased levels in ovarian cancer 93 , and decreased levels upon 17-estradiol (E2) treatment in the MCF-7 breast cancer cell line 94 and was shown in a cell line experiment to influence anticancer drug chemosensitivity 95 .…”